Second autologous transplantation after failure of a first autologous transplant in 18 patients with non-Hodgkin's lymphoma
- PMID: 15448666
- DOI: 10.1038/sj.thj.6200545
Second autologous transplantation after failure of a first autologous transplant in 18 patients with non-Hodgkin's lymphoma
Abstract
High-dose chemotherapy and autologous marrow or peripheral stem cell support offers the best chance of cure in some subgroups of patients with non-Hodgkin's lymphoma (NHL). Less is known about the role of a second course of myeloablative chemotherapy in patients who relapse after a first autologous transplant. The aim of this retrospective study was to evaluate the disease outcome, morbidity and mortality associated with second autologous transplantation in patients with NHL. Between 1985 and 2001, 225 patients who had received autologous transplantation for NHL in two institutions in Lyon relapsed. Of these 225 patients 18 underwent a second autologous transplantation. The median age at second transplant was 41 years. There were six indolent lymphomas and 12 aggressive lymphomas. The median follow-up from the second transplant was 42 months. The OS rate at 2 and 5 years were 58 and 27%, respectively. The PFS rate at 2 and 5 years was 36%. Five patients are alive without disease 20 to 100 months after the second transplant. Seven patients died of disease recurrence. Four (22%) toxic deaths occurred: one of pulmonary fibrosis, one of fungal infection and cardiac failure and two of acute leukaemia. A minority of patients with NHL recurrence after a first transplant can be cured by a second course of myeloablative chemotherapy at the cost however of high-risk toxic death.
Similar articles
-
'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.Bone Marrow Transplant. 2002 Dec;30(12):885-91. doi: 10.1038/sj.bmt.1703772. Bone Marrow Transplant. 2002. PMID: 12476281
-
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.Eur J Haematol. 2007 Feb;78(2):93-101. doi: 10.1111/j.1600-0609.2006.00796.x. Eur J Haematol. 2007. PMID: 17313557 Clinical Trial.
-
Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.Biol Blood Marrow Transplant. 2006 Oct;12(10):1065-72. doi: 10.1016/j.bbmt.2006.06.006. Biol Blood Marrow Transplant. 2006. PMID: 17084370
-
Outcome and toxicity of salvage treatment on patients relapsing after autologous hematopoietic stem cell transplantation--experience from a single center.Hematology. 2003 Jun;8(3):145-50. doi: 10.1080/1024533031000107479. Hematology. 2003. PMID: 12745647 Review.
-
[Salvage therapy in relapsed or refractory malignant lymphoma].Nihon Rinsho. 2000 Mar;58(3):699-703. Nihon Rinsho. 2000. PMID: 10741149 Review. Japanese.
Cited by
-
Therapeutic options for patients with Hodgkin's disease and non-Hodgkin's lymphoma who relapse after autologous transplant.Curr Treat Options Oncol. 2005 Jul;6(4):279-87. doi: 10.1007/s11864-005-0032-z. Curr Treat Options Oncol. 2005. PMID: 15967081 Review.
-
Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant.Biol Blood Marrow Transplant. 2008 Aug;14(8):904-12. doi: 10.1016/j.bbmt.2008.05.021. Biol Blood Marrow Transplant. 2008. PMID: 18640574 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical